Seth Walker

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.3K citations · Full text

Mendelian Disorder, Genetics, Ivacaftor Combination Regimen +2

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation

K. De Boeck, À. Munck, Seth Walker et al. · Journal of Cystic Fibrosis · 2014 · 379 citations · Full text

Medicine, Non-g551d Gating Mutation, Pathology

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial

Félix Ratjen, Christopher Hug, Gautham Marigowda et al. · The Lancet Respiratory Medicine · 2017 · 291 citations

Pulmonary Fibrosis, Medicine, Placebo-controlled Phase 3

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study

Margaret Rosenfeld, Claire Wainwright, Mark Higgins et al. · The Lancet Respiratory Medicine · 2018 · 262 citations · Full text

Medicine, Cftr Gating Mutation, Pediatrics +1

A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis

Seth Walker, Patrick A. Flume, John McNamara et al. · Journal of Cystic Fibrosis · 2019 · 54 citations · Full text